Item 5.02 Departure of Directors or Certain Officers; Election of Directors;


           Appointment of Certain Officers; Compensatory Arrangements of Certain
           Officers.

On December 17, 2019, Mani Mohindru, Chief Financial Officer and Chief Strategy Officer of Cara Therapeutics, Inc. (the "Company"), gave notice of her resignation, effective December 20, 2019, to accept a new opportunity with a privately held company. The Company has commenced a search for Dr. Mohindru's replacement. Dr. Mohindru's departure is not due to a dispute or disagreement with the Company.

Effective immediately following Dr. Mohindru's departure, Richard Makara, the Company's Vice President, Head of Accounting & Controller, assumed Dr. Mohindru's responsibilities on an interim basis. As of that date, Mr. Makara assumed the position of the Company's principal financial officer and principal accounting officer until such time as his successor is appointed, or until his earlier resignation or removal.

Mr. Makara, 49, has served the Company in various capacities since October 2014, most recently serving as VP, Head of Accounting & Controller from November 2018 to present. Prior to joining the Company, he served as Director of Accounting at Purdue Pharma from June 2010 to October 2014. Before joining Purdue, he served as an auditor for PricewaterhouseCoopers from 1992 to 2009. Mr. Makara received his B.S. in Accounting from Purdue University. Mr. Makara is a certified public accountant.

There is no family relationship between Mr. Makara and any director or executive officer of the Company and he has no direct or indirect material interest required to be disclosed pursuant to Item 404(a) of Regulation S-K.


                                       2

© Edgar Online, source Glimpses